The present disclosure relates to novel lymphoid-specific tyrosine phosphatase (LYP, encoded by the PTPN22 gene) inhibitors, and to methods of making and using the novel LYP inhibitors. Thus, the compounds according to the disclosure may be used for treating diseases or disorders associated with PTPN22 genetic polymorphism, including type 1 diabetes, rheumatoid arthritis, systemic lupus erythematosis, Graves' disease, Addison's disease, vitiligo, juvenile arthritis, Hashimoto thyroiditis, and other rarer diseases. Furthermore, these LYP inhibitors may be served for a novel class of cancer immunotherapy. The compounds can be injected or orally administered.

The present invention relates to agents and methods for treating autism spectrum disorders, such as Rett Syndrome.

The present invention relates to agents and methods for treating autism spectrum disorders, such as Rett Syndrome.

The present invention includes a method of preventing and/or treating a fibrotic lung disease in a subject. In certain embodiments, the method comprises administering to the subject a thyroid receptor β-agonist. The invention further comprises compositions useful within the invention, as well as kits comprising compositions useful within the invention.

A method of treating COVID-19 in a patient. The patient may be in moderate to advanced stages of COVID-19 infection. The method includes administering to the patient a therapeutically effective amount of at least one antagonist or inhibitor of chemokine receptor CXCR4. The at least one antagonist or inhibitor of chemokine receptor CXCR4 is distinct from hydroxychloroquine.

A method of treating COVID-19 in a patient. The patient may be in moderate to advanced stages of COVID-19 infection. The method includes administering to the patient a therapeutically effective amount of at least one antagonist or inhibitor of chemokine receptor CXCR4. The at least one antagonist or inhibitor of chemokine receptor CXCR4 is distinct from hydroxychloroquine.

An enzymatic sensor configured to determine the concentration of levodopa present in a sample according to a current or a resonant frequency produced in response to levodopa interactions with L-amino acid decarboxylase present in the sensor. A processor associated with the sensor determines levodopa concentration and produces dose recommendation or output according to levodopa concentration.

An enzymatic sensor configured to determine the concentration of levodopa present in a sample according to a current or a resonant frequency produced in response to levodopa interactions with L-amino acid decarboxylase present in the sensor. A processor associated with the sensor determines levodopa concentration and produces dose recommendation or output according to levodopa concentration.

The presently disclosed subject matter provides methods for treating and diagnosing neurological diseases or disorders using intranasal administration of glutamate carboxypeptidase II (GCP-II) inhibitors in a subject. Methods for imaging GCP-II in a subject, including imaging of the brain and/or peripheral nervous system, also are provided.

The presently disclosed subject matter provides methods for treating and diagnosing neurological diseases or disorders using intranasal administration of glutamate carboxypeptidase II (GCP-II) inhibitors in a subject. Methods for imaging GCP-II in a subject, including imaging of the brain and/or peripheral nervous system, also are provided.